Novo Nordisk, underway with key launches, reveals $2.58B manufacturing investment

Amid the important launches for oral diabetes drug Rybelsus and obesity medicine Wegovy, the only problem for Novo Nordisk, it seems, is meeting growing demand.

On Monday, the Danish drugmaker revealed a move that will help accomplish that as it will invest $2.58 billion into expanding production capacity.